Product Name:

XL-184(Cabozantinib)

Request XL-184(Cabozantinib)
CAT#: A-1089    

Chemical Structure

Price of XL-184(Cabozantinib)


We offer a substantial discount on larger orders,
please inquire via sales@activebiochem.com
or Fax: 1-201-884-1288(USA Fax#)

We match the lowest price on market.

Recommended Inhibitors

Biological Activity

XL184 is an orally bioactive, multitargeted inhibitor of tumor growth, metastasis and angiogenesis, simultaneously targeting c-MET, RET and VEGFR2 with IC50s at low nM.
Technical Data
Formula:    C28H24FN3O5.C4H6O5
M.Wt:     635.61
CAS#:     1235470-37-7
Purity:     >99%
Solubility : DMSO
Storage Conditions :Room temperature, or -20ºC for 2 year.
QC Data
XL-184(Cabozantinib) MSDS XL-184 CoA
Reference
[CITATION] A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid ˇ­
R Salgia, S Sherman, DS Hong, CS Ng, J Fryeˇ­ - J Clin Oncol, 2008
[PDF] Phase 2 study of XL184 (BMS-907351), an inhibitor of MET, VEGFR2, and RET in patients with progressive glioblastoma
P Wen, M Prados, D Schiff, D Reardonˇ­ - J Clin Oncol, 2010 - exelixis.com
XL184 (BMS-907351) is being co-developed by Exelixis and Bristol-Myers Squibb ... VEGF and HGF have been implicated as major paracrine ... However, selective inhibition of VEGF signaling has been ... XL184 simultaneously inhibits VEGF and MET pathways,